new20 Antibody

What is the new20 antibody and what organism does it target?

The new20 antibody is a polyclonal antibody developed against the recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843) new20 protein. This antibody specifically targets yeast proteins and has been validated for use in ELISA and Western Blot applications . The target protein (new20) is currently classified as an "uncharacterized protein" in S. pombe, suggesting ongoing research to fully elucidate its function and cellular role.

What are the optimal storage conditions for maintaining new20 antibody activity?

For long-term storage, the new20 antibody should be maintained at either -20°C or -80°C to preserve its activity and specificity . For working solutions, it is advisable to keep aliquots at 4°C for up to one week to minimize freeze-thaw cycles that can degrade antibody performance . This follows standard protocols for antibody preservation that protect the structural integrity of the immunoglobulin.

What validated applications exist for the new20 antibody?

The new20 antibody has been specifically validated for ELISA and Western Blot (WB) applications . These techniques allow researchers to detect and quantify the presence of new20 protein in experimental samples. The polyclonal nature of this antibody means it can recognize multiple epitopes on the target protein, potentially increasing sensitivity while requiring careful optimization to minimize background signals.

How should positive and negative controls be designed for new20 antibody validation experiments?

For proper validation of the new20 antibody, researchers should implement a comprehensive control strategy:

Positive Controls:

• Use the recombinant immunogen protein (200μg provided with the antibody) as a primary positive control

• Include wild-type S. pombe lysates that naturally express the new20 protein

• Consider using overexpression systems in yeast to generate samples with elevated new20 levels

Negative Controls:

• Utilize the pre-immune serum (1ml provided with the antibody kit) as a critical negative control

• Include lysates from new20 knockout strains if available

• Test specificity against related yeasts that lack new20 homologs

This balanced approach helps distinguish between specific binding and background signal, especially important when working with uncharacterized proteins.

What is the recommended protocol for optimizing Western blot conditions with the new20 antibody?

When optimizing Western blot protocols for the new20 antibody, researchers should systematically evaluate:

• Antibody dilution range: Begin with 1:500-1:2000 dilutions and adjust based on signal-to-noise ratio

• Blocking conditions: Test both BSA and non-fat milk blockers at 3-5% concentrations

• Incubation parameters: Compare overnight incubation at 4°C versus 1-2 hours at room temperature

• Detection systems: Evaluate chemiluminescence versus fluorescence-based detection

The following parameters should be documented during optimization:

This methodical approach will establish reproducible conditions for detecting the new20 protein while minimizing non-specific binding.

How can researchers assess cross-reactivity of the new20 antibody with homologous proteins in other yeast species?

Assessing cross-reactivity requires a systematic approach to determine antibody specificity across species boundaries:

• Perform sequence alignment analysis of the new20 protein (UniProt: G2TRS2) against potential homologs in related yeast species using tools like BLAST or HMMER

• Generate lysates from multiple yeast species with varying evolutionary distances from S. pombe

• Conduct Western blot analysis with standardized protein loading (confirmed by total protein staining)

• Compare band patterns and intensities to determine species-specific recognition

• Validate findings using immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody

This approach helps establish the taxonomic range of antibody utility while revealing potential epitope conservation across species.

What strategies can be employed to improve signal detection when the new20 protein is expressed at low levels?

When dealing with low-abundance targets, several signal enhancement strategies can be implemented:

• Sample enrichment techniques:

  • Subcellular fractionation to concentrate compartments where new20 is predominantly expressed

  • Immunoprecipitation to concentrate the target protein prior to analysis

  • Use of proteasome inhibitors if rapid degradation is suspected

• Signal amplification methods:

  • Employ high-sensitivity detection substrates for Western blotting

  • Utilize tyramide signal amplification for immunohistochemistry

  • Consider using biotin-streptavidin systems to enhance detection sensitivity

• Technical modifications:

  • Extend primary antibody incubation time to 48 hours at 4°C

  • Optimize sample loading to maximum capacity without lane distortion

  • Consider using transfer conditions optimized for the molecular weight of new20

These approaches can significantly improve detection of low-abundance targets while maintaining specificity.

How does the specificity of the new20 polyclonal antibody compare to monoclonal alternatives in research applications?

The new20 antibody is available as a polyclonal preparation purified using Protein A/G . This polyclonal nature offers distinct advantages and limitations compared to hypothetical monoclonal alternatives:

Researchers should consider these trade-offs when selecting between antibody types for specific experimental designs, particularly when working with uncharacterized proteins like new20.

What bioinformatic approaches can predict functional domains within the new20 protein to better interpret antibody binding results?

Understanding the structural and functional domains of the new20 protein can provide critical context for interpreting antibody binding patterns. Researchers should employ a multi-layered bioinformatic approach:

• Sequence-based prediction:

  • Analyze the new20 sequence (UniProt: G2TRS2) using domain prediction tools like InterProScan, SMART, and Pfam

  • Identify conserved motifs using MEME and similar pattern recognition algorithms

  • Apply disorder prediction using tools like PONDR to identify structured vs. unstructured regions

• Structural modeling:

  • Generate 3D structural predictions using AlphaFold2 or similar tools

  • Map predicted epitopes onto the structural model to visualize accessibility

  • Identify potential post-translational modification sites that might affect antibody recognition

• Evolutionary analysis:

  • Perform phylogenetic analysis to identify conserved regions across homologs

  • Calculate selection pressures across the protein sequence to identify functionally important regions

  • Map conservation scores onto structural models to identify surface-exposed conserved patches

These computational approaches provide a framework for understanding which regions of new20 are likely being recognized by the antibody, informing experimental design and interpretation.

What are the most common causes of false positives when using the new20 antibody, and how can researchers mitigate them?

• Cross-reactivity with related proteins:

  • Validate specificity using knockout controls if available

  • Perform peptide competition assays to confirm epitope specificity

  • Compare banding patterns with predicted molecular weight of new20

• Non-specific binding to sample components:

  • Optimize blocking conditions using different blocking agents (BSA, milk, commercial blockers)

  • Increase washing stringency by adjusting salt and detergent concentrations

  • Pre-absorb antibody with lysates from organisms lacking new20

• Detection system artifacts:

  • Include secondary-only controls to identify non-specific secondary antibody binding

  • Use appropriate filters when employing fluorescent detection systems

  • Compare results across different detection methodologies

Implementing these strategies reduces the likelihood of misinterpreting experimental results due to false positive signals.

How can researchers quantitatively assess batch-to-batch variation in new20 antibody performance?

Ensuring consistency across antibody batches is essential for experimental reproducibility. A systematic approach to quantifying batch variation includes:

• Establish reference standards:

  • Create and preserve aliquots of positive control samples from initial validation

  • Generate standard curves using recombinant new20 protein at known concentrations

• Perform comparative analysis:

  • Test new batches in parallel with reference batch using identical protocols

  • Quantify signal intensities at multiple antibody dilutions

  • Calculate correlation coefficients between batch performances

• Document performance metrics:

  • Record detection limits for each batch

  • Measure signal-to-noise ratios under standardized conditions

  • Assess recognition patterns across multiple experimental samples

This systematic approach enables researchers to confidently compare results across experiments using different antibody batches.

How might the new20 antibody be adapted for live-cell imaging applications in yeast research?

Adapting the new20 antibody for live-cell imaging requires innovative approaches to overcome the cell wall barrier and maintain cell viability:

• Antibody modification strategies:

  • Fragment the full IgG to generate Fab or scFv derivatives with improved penetration

  • Conjugate directly to bright, photostable fluorophores optimized for yeast imaging

  • Consider cell-penetrating peptide conjugation to enhance internalization

• Cell preparation techniques:

  • Develop partial cell wall digestion protocols that maintain cell viability

  • Optimize spheroplasting conditions for transient permeabilization

  • Explore microinjection techniques for direct antibody delivery

• Genetic approaches:

  • Generate strains expressing fluorescently-tagged new20 for parallel validation

  • Create split-GFP systems where the antibody carries one fragment for in vivo complementation

  • Develop intrabodies derived from the new20 antibody sequence optimized for intracellular expression

These approaches could expand the utility of new20 antibodies beyond traditional fixed-cell or biochemical applications, enabling dynamic studies of protein localization and interaction.

What computational approaches can predict the epitopes recognized by the new20 polyclonal antibody?

Identifying the epitopes recognized by the new20 polyclonal antibody involves integrative computational approaches:

• Linear epitope prediction:

  • Apply algorithms like BepiPred and ABCpred to identify potential linear epitopes

  • Calculate surface accessibility and hydrophilicity profiles

  • Analyze amino acid composition for regions enriched in charged/polar residues

• Conformational epitope mapping:

  • Use EpiPred or similar tools that incorporate structural information

  • Apply molecular dynamics simulations to identify stable surface-exposed regions

  • Calculate electrostatic potentials to identify charged patches likely to be immunogenic

• Experimental validation design:

  • Generate a peptide array spanning the new20 sequence for epitope mapping

  • Design mutational scanning experiments targeting predicted epitope regions

  • Develop competition assays using synthesized peptides representing predicted epitopes

Understanding the epitope landscape recognized by the polyclonal preparation helps researchers interpret binding patterns and design more specific detection strategies for the new20 protein.